Pharmafile Logo
Pharmafocus logo
Advanced Search
needles

BTG acquires promising oncology pipeline in Galil Medical takeover

May 9, 2016
Manufacturing and Production, Research and Development, Sales and Marketing $84 million, BTG, cryoablation, galil medical, oncology, takeover

BTG (LSE: BTG) has announced that is has agreed to acquire Galil Medical, a leading provider of cryoablation products for …

News
allergan

Phase III trial meets primary endpoint for Allergan’s fibroid treatment

May 9, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Allergan, fibroid, phase 3, phase III, ulipristal, ulipristal acetate, uterine fibroid

Allergan (NYSE: AGN), in collaboration with Gedeon Richter, has announced positive results from a pivotal Phase III trial evaluating the …

News
stocks1

Weekly Movers: Bind Therapeutics, Sarepta, Idexx…

May 9, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Pfizer (NYSE: PFE) and Amgen (Nasdaq: AMGN) are rumoured to be considering a bid for Medivation just as French drug …

Feature
stocks2

Clovis cuts staff by 35% after FDA knock back on lung cancer drug

May 6, 2016
Manufacturing and Production, Research and Development, Sales and Marketing FDA, Q1 results, clovis, failure, job cuts, job losses, rociletinib, workforce

Clovis Oncology (NASDAQ: CLVS) is set to cut up to 35% of its workforce following the US Food and Drug …

News

NICE recommends Sanofi, Amgen cholesterol drugs

May 6, 2016
Medical Communications, Sales and Marketing Amgen, Draft Guidance, NHS, NICE, Repatha, Sanofi, cardiovascular disease, cholesterol, final draft guidance, high cholesterol, praluent, recommendation, treatment

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending two new drugs for the …

News
fda_logo-web

KemPharm’s pain drug fails to get FDA committee backing for abuse-deterrent capabilities; shares plunge

May 6, 2016
Medical Communications, Sales and Marketing

Shares in KemPharm (Nasdaq: KMPH) more than halved in pre-market trading after a US Food and Drug Administration advisory panel …

News
tug-of-war

Focus: Medivation tug-of-war rumbles on

May 6, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, AstraZeneca, Medivation, Pfizer, Sanofi, billion dollar, competition, oncology, pipeline, promising, takeover, tug of war

Medivation (NASDAQ: MDVN) has been making all the headlines as a list of suitors’ line up, all vying to secure …

Feature
merck

Merck & Co Q1 sales hurt by generics, currency impact

May 6, 2016
Medical Communications, Sales and Marketing Financial, Merck & Co, Q1, Revenye, earnings, results, sales

US pharma major Merck & Co (NYSE: MRK) posted a drop in first-quarter sales impacted the launch of generic competition …

News
papa

Valeant announces new patient access and pricing committee; vows to correct past “mistakes”

May 6, 2016
Medical Communications, Sales and Marketing Valeant, joseph papa, new committee, patient access, price gouging, pricing

Valeant (NYSE: VRX) has announced the establishment of a new patient access and pricing committee that will be responsible for …

News
pfizerbrussels

Pfizer teams up with Wave Life Sciences for metabolic disease research

May 6, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pfizer, metabolic disease, nucelic acid therapies, partnership, wave life sciences

Pfizer (NYSE: PFE) has entered into a research, license and option agreement with Wave Life Sciences (NASDAQ: WVE) for the …

News
amgen_flag

Amgen looking to join the fray, mulling Medivation bid – Reports

May 5, 2016
Research and Development, Sales and Marketing Amgen, AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi

Biotech firm Amgen (Nasdaq: AMGN) is mulling a bid for Medivation (Nasdaq: MDVN), the latest to join the growing list …

News
eyeimagenotext-1

Valeant’s Bausch + Lomb teams up with IBM for cataract surgery app

May 5, 2016
Research and Development Bausch and Lomb, Valeant, app, cataract, cataract surgery, ibm, ipad, iphone, surgeons

IBM (NYSE: IBM) and Bausch + Lomb, a wholly owned subsidiary of Valeant (NYSE: VRX), have announced a partnership that …

News
sanofi_hq__boetie_hall

Sanofi sends letter to Medivation board; claims shareholders want takeover

May 5, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Medivation, Sanofi, board, brandicourt, hostile, shareholders, takeover

The CEO of Sanofi has issued a strongly worded letter to the board at Medivation, indicating that shareholders support their …

News
2174264_eisai_logo-web

Eisai says European Commission backs Halaven to treat of advanced Liposarcoma in Europe

May 5, 2016
Research and Development, Sales and Marketing EC, Eisai, US FDA, oncology, regulation, soft tissue sarcoma

The European Commission has backed marketing for the Japanese drug major Eisai’s (TYO: 4523) Halaven (eribulin) to treat advanced soft …

News
doc_writing

One in three antibiotic prescriptions in US unnecessary, says CDC

May 5, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDC, antibiotic, prescribing, prescriptions, unnecessary

Approximately 30% of all prescriptions of antibiotics in the United States are unnecessary, according to new data published by the …

News
headquarters_3_web

Eli Lilly’s cancer drug candidate scores FDA priority review

May 5, 2016
Eli Lilly, US FDA, oncology, regulation

US drugmaker Eli Lilly (NYSE: LLY) said the US Food and Drug Administration (FDA) has granted priority review for its …

News

Bayer’s liver cancer drug meets primary endpoint in late stage trial

May 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Stivarga, late stage trial, liver cancer, phase III, regorafenib, trial

Bayer has announced positive results from a late-stage trial evaluating Stivarga (regorafenib) tablets for the treatment of patients with unresectable …

News

Biogen to spin off its haemophilia business

May 4, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Biogen, Business, alprolix, eloctate, haemophilia, hemophilia, spin off, spin-off

Biogen (NASDAQ: BIIB) has announced plans to spin off its haemophilia business as an independent, publicly traded company. To be …

News

Nice extends price-negotiation talks for PTC’ muscle wasting drug

May 4, 2016
Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, NICE, PTC Therapeutics, Translarna, market access, regulation

UK regulators have extended the cost negotiation talks with PTC Therapeutics (Nasdaq: PTCT) by a week for the drug to …

News

Pfizer revenue jumps 20%; ups FY16 outlook

May 4, 2016
Research and Development, Sales and Marketing Pfizer, Q1, earnings, results, revenue, sales

US pharma giant Pfizer (NYSE: PFE) reported a 20% jump in first-quarter revenue boosted by performance of its new cancer …

News
The Gateway to Local Adoption Series

Latest content

Faron Pharmaceuticals appoints Heikki Jouttijärvi as Chief Technical Officer

April 2, 2026

Cambridge’s Grassroots Life Sciences Showcase Branches Out to Oxford & London

April 1, 2026

Doccla appoints Michael Macdonnell as Chief Strategy & Growth Officer and Deputy CEO

April 1, 2026

Bramacare launches new AI platform to improve eating disorder care

March 31, 2026

Doccla appoints Jonathan Serjeant as Chief Medical Officer

March 31, 2026